Payment overview · 2025
General Payments
$2,982.87
171 reported records · 28 companies
Healthcare provider profile · identity verified
Lisa M Esterle, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · MEDINA, OH · NPI 1427029248
Verified facts
What the public records show
CMS Open Payments records show Lisa M Esterle, D.O. received $2,982.87 in general payments during 2025 across 171 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 43 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Mounjaro, Nurtec Odt, Ozempic, Paxlovid, Qulipta, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Kerendia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $572.49 | 19.2% | 24 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $398.37 | 13.4% | 29 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $320.09 | 10.7% | 31 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $221.57 | 7.4% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $161.95 | 5.4% | 11 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $159.27 | 5.3% | 6 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $145.26 | 4.9% | 7 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $104.33 | 3.5% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $102.68 | 3.4% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $89.42 | 3.0% | 4 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $74.50 | 2.5% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $73.07 | 2.5% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $71.43 | 2.4% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $61.65 | 2.1% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $43.40 | 1.4% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $42.00 | 1.4% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $41.09 | 1.4% | 2 | 2025 |
| Neos Therapeutics, LP | Unresolved — no canonical attribution shown | $40.81 | 1.4% | 2 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $39.81 | 1.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.50 | 1.2% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $36.13 | 1.2% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $31.19 | 1.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.03 | 0.7% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $21.84 | 0.7% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $20.85 | 0.7% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.27 | 0.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.25 | 0.6% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.62 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,982.87 | 171 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $444.47 | 17 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $290.72 | 19 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $287.14 | 29 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $206.34 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $173.23 | 18 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $159.27 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $158.26 | 9 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $150.04 | 13 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $145.26 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $142.45 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $131.63 | 7 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $104.33 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $102.68 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $93.06 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $92.70 | 9 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $74.50 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $73.07 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $63.31 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $61.65 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $52.83 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $52.44 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $48.32 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $46.91 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $46.91 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $43.40 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $42.00 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $41.10 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $41.09 | 2 | 2025 |
Source payment records
|
|||||
| Adzenys XR-ODT Normalized: adzenys xr odt |
Drug | Neos Therapeutics, LP | $40.81 | 2 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $39.81 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $36.50 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $31.19 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $24.52 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.03 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $21.84 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $20.85 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.25 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.25 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 159 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 69 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 86 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 68 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 19 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 78 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
48 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
21 | 13 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
69 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
159 | 41 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
78 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
159 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 429 | 91 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 425 | 105 |
| Atorvastatin Calcium | Atorvastatin Calcium | 400 | 113 |
| Lisinopril | Lisinopril | 289 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 263 | 70 |
| Furosemide | Furosemide | 241 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 236 | 67 |
| Alprazolam | Alprazolam | 235 | 35 |
| Gabapentin | Gabapentin | 231 | 55 |
| Metformin Hcl | Metformin Hcl | 219 | 45 |
| Lorazepam | Lorazepam | 196 | 41 |
| Omeprazole | Omeprazole | 180 | 44 |
| Sertraline Hcl | Sertraline Hcl | 180 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 163 | 52 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 162 | 25 |
| Eliquis | Apixaban | 159 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 159 | 50 |
| Potassium Chloride | Potassium Chloride | 152 | 32 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 145 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 143 | 34 |
| Meloxicam | Meloxicam | 143 | 29 |
| Losartan Potassium | Losartan Potassium | 129 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 129 | 42 |
| Fenofibrate | Fenofibrate | 124 | 27 |
| Trazodone Hcl | Trazodone Hcl | 118 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 117 | 24 |
| Tramadol Hcl | Tramadol Hcl | 117 | 32 |
| Prednisone | Prednisone | 113 | 62 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 112 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 104 | 30 |
| Allopurinol | Allopurinol | 101 | 21 |
| Temazepam | Temazepam | 101 | 18 |
| Cefdinir | Cefdinir | 94 | 75 |
| Bupropion Xl | Bupropion Hcl | 87 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 86 | 23 |
| Jardiance | Empagliflozin | 86 | 19 |
| Montelukast Sodium | Montelukast Sodium | 86 | 19 |
| Carvedilol | Carvedilol | 85 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 78 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 75 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 12 |
| Farxiga | Dapagliflozin Propanediol | 69 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 20 |
| Celecoxib | Celecoxib | 68 | 15 |
| Ozempic | Semaglutide | 68 | 17 |
| Pregabalin | Pregabalin | 67 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 20 |
| Simvastatin | Simvastatin | 63 | 19 |
| Atenolol | Atenolol | 60 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 58 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 57 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 40 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 12 |
| Synthroid | Levothyroxine Sodium | 48 | 15 |
| Valsartan | Valsartan | 48 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 47 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | suppressed |
| Finasteride | Finasteride | 47 | 11 |
| Levetiracetam | Levetiracetam | 46 | suppressed |
| Ondansetron Odt | Ondansetron | 46 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 44 | suppressed |
| Spironolactone | Spironolactone | 42 | 12 |
| Estradiol | Estradiol | 41 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | suppressed |
| Levofloxacin | Levofloxacin | 41 | 27 |
| Oxycodone Hcl | Oxycodone Hcl | 41 | 11 |
| Alendronate Sodium | Alendronate Sodium | 40 | 12 |
| Diazepam | Diazepam | 40 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 39 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 39 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 39 | 12 |
| Baclofen | Baclofen | 38 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 38 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 36 | 15 |
| Fluconazole | Fluconazole | 35 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | 11 |
| Ibuprofen | Ibuprofen | 34 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 34 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Kerendia | Finerenone | 31 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 24 |
| Meclizine Hcl | Meclizine Hcl | 26 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Nystatin | Nystatin | 25 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 20 |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 15 |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Prolia | Denosumab | 21 | 13 |
| Tobramycin | Tobramycin | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 20 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 15 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,982.87 · 171 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Adzenys XR-ODT, Auvelity, BREZTRI, CAPVAXIVE, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, Dyanavel XR, ELIQUIS, FANAPT, FARXIGA, GARDASIL 9, GEMTESA, GVOKE HYPOPEN, INSPIRE, JARDIANCE, KRYSTEXXA, Kerendia, Korlym, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, QULIPTA, Qelbree, REPATHA, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, VIBERZI, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XYOSTED, YUPELRI, ZAVZPRET, ZENPEP, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error